(Q38686463)

5 September 2017

1 reference

title

Polyunsaturated fatty acids, prostaglandins, and schizophrenia (English)

1 reference

5 September 2017

0 references

1 reference

van Kammen DP

1

1 reference

5 September 2017

Yao JK

series ordinal

2

1 reference

5 September 2017

Goetz K

series ordinal

3

1 reference

5 September 2017

language of work or name

English

0 references

publication date

1 January 1989

1 reference

Annals of the New York Academy of Sciences

5 September 2017

1 reference

5 September 2017

559

1 reference

5 September 2017

411-423

1 reference

Schizophrenia as a prostaglandin deficiency disease

5 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Schizophrenia: Reconciliation of the dopamine, prostaglandin, and opioid concepts and the role of the pineal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Lipid Asymmetry in Membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Schizophrenia: The role of abnormal essential fatty acid and prostaglandin metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Fatty acid profiles in mental disease. Part 1. Linolenate variations in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Increased content of immunoreactive prostaglandin E in cerebrospinal fluid of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Elevated levels of prostaglandin E2 and thromboxane B2 in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Plasma prostaglandin E2 metabolite--measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2--in twins with schizophrenic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Reduced PGE1 stimulated 3H-cAMP accumulation in platelets from schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Reduced cyclic AMP production in the blood platelets from schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Prostaglandins, platelets, and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Schizophrenia and reduced cyclic AMP production: evidence for the role of receptor-linked events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Prostaglandin receptor sensitivity in psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Postsynaptic supersensitivity in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Platelet alpha-adrenergic binding and biochemical responsiveness in depressed patients and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Rapid antidepressant response to alprazolam in depressed patients with high catecholamine output and heterologous desensitization of platelet adenylate cyclase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Penicillin and essential fatty acid supplementation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Predicting Drug-Free Improvement in Schizophrenic Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

MAO activity, csf amine metabolites, and drug-free improvement in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Modification of dyskinesias following the intrastriatal injection of prostaglandins in the rodent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Prostaglandins contribute to the vasodilation induced by nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Dopamine receptor subtype imbalance in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Liberation of catecholamines from blood platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

Variability in schizophrenia. Reflection of a regulatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

CSF Prostaglandin Levels in Depressed and Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1989.TB22626.X

10.1111/J.1749-6632.1989.TB22626.X

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference